Background. Few studies have examined the effectiveness of pneumococcal vaccination (alone or with influenza vaccination) in improving hemodialysis patient outcomes. We aimed to describe vaccination rates between [2003][2004][2005] and to study the effects on outcomes. Methods. For 118 533 prevalent patients who initiated hemodialysis !90 days before 1 November 2003, had Medicare Part A and Part B and were aged !18 years, and alive through 31 October 2005, Cox proportional hazards models were used to assess pneumococcal vaccination effects on subsequent hospitalization and mortality, adjusting for demographics and comorbidity. Results. The 21% of patients who received vaccinations were older; a higher proportion were white, with diabetes as cause of end-stage renal disease and more comorbidity. Pneumococcal vaccination was associated with a statistically significant decreased mortality hazard [hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.90-0.98], cardiac death (HR 0.91, 95% CI 0.85-0.97) and hospitalization for bacteremia/viremia/septicemia (HR 0.95, 95% CI 0.91-1.00). The mortality hazard was 0.73 (95% CI 0.68-0.78) for patients who received pneumococcal and influenza vaccinations. Conclusions. The small but significant association between pneumococcal vaccination and lower mortality risk was seen despite factors associated with poor outcomes in patients most likely to be vaccinated. Pneumococcal and influenza vaccines may have beneficial synergistic effects. Hemodialysis patients may benefit from revaccination more frequently than the recommended 5-year intervals.
Introduction
Infection is common in patients with end-stage renal disease (ESRD); it is the second leading cause of death and a major contributor to hospitalizations [1] . This may be partly due to uremia-related impaired immune function and to exposure to infections through dialysis access, particularly with use of catheters. The three most common infections in ESRD patients are urinary tract infections, sepsis and pneumonia. The rate of hospital admissions for pneumonia among prevalent hemodialysis patients is 73/1000 patient-years [1] . The Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention recommends a one-time revaccination with pneumococcal polyvalent vaccine after 5 years for patients with chronic renal failure or nephritic syndrome; the National Kidney Foundation recommends pneumonia vaccination every 3-5 years [2] . However, evidence suggests that a proportion of hemodialysis patients may not demonstrate adequate serum response [3, 4] , and many dialysis patients may lack detectable antibody levels 3-5 years after pneumococcal vaccine administration [4, 5] . Thus, some dialysis centers promote pneumococcal immunization as frequently as every 2 years. Published reports suggest differences among dialysis provider groups in pneumococcal immunization practice [6] ; nevertheless, little research has been published on the effectiveness of pneumococcal immunization or administration frequency in improving outcomes among dialysis patients. The goal of this study was to describe pneumococcal vaccination rates between 2003 and 2005, and to study the observed association of pneumococcal vaccination with pneumonia-related outcomes.
Materials and methods
The study population consisted of prevalent patients who initiated hemodialysis therapy at least 90 days before 1 November 2003, had Medicare Part A and Part B program coverage and were aged !18 years, alive and on Medicare through 31 October 2005. These criteria allowed for a 2-year period to assess pneumococcal vaccination status and other comorbid conditions at baseline. Claims were searched from 1 November 2003 through 31 October 2005, for evidence of pneumococcal vaccination [Current Procedural Terminology/Health Care Common Procedure Coding System (HCPCS) codes 90732 and G0009]. Influenza vaccination and comorbid conditions were also defined from claims during this 2-year entry period. Patients were followed from 1 November 2005 through 1 May 2006 (follow-up period) for the following outcomes: all-cause mortality, all-cause hospitalization, pneumonia hospitalization, hospitalization for bacteremia/viremia/septicemia and hospitalization for respiratory infection. Sensitivity analyses using a 1-year follow-up period were also performed. Cox proportional hazards models were used to assess the impact of pneumococcal vaccination on subsequent hospitalization and mortality, adjusting for patient demographics and comorbidity. We also adjusted for influenza vaccination since the pneumococcal and influenza vaccinations were sometimes given in conjunction. Additional sensitivity analyses were performed examining associations of receiving more than one pneumococcal vaccination with outcomes.
Comorbid conditions
Based on a method previously validated for diabetes [7] , patients were defined as having a comorbid condition if an International Classification of Diseases, Ninth edition, Clinical Modification code for the condition appeared on one or more Part A institutional claims (inpatient hospitalization, skilled nursing facility or home health agency) or two or more Part A outpatient claims or Part B physician/supplier claims <1 year apart or one or more Part A outpatient claims and one or more Part B physician/supplier claims <1 year apart. Comorbid conditions defined for this study were atherosclerotic heart disease, congestive heart failure, cerebrovascular accident/transient ischemic attack, peripheral vascular disease, other cardiac disease, chronic obstructive pulmonary disease, gastrointestinal bleeding, liver disease, dysrhythmia, cancer and diabetes.
Vaccinations
HCPCS codes 90732 and G0009 were used to search for pneumococcal vaccination. HCPCS codes 90656, 90658, 90659, 90660 and G0008 were used to search for influenza vaccination during both influenza vaccination seasons that occurred during the entry period.
All analyses were conducted using SAS v9.1 (Cary, NC).
Results
The cohort of 118 533 patients had the following characteristics: 17% were aged !75 years, 47% were women, 50% were white, 40% had diabetes as cause of renal failure and 45% had been on dialysis for !5 years (Table 1) . During the 2-year period from 31 October 2003, through 31 October 2005, 21% of the cohort received a pneumococcal vaccination. These patients were older, and a higher proportion were white, with diabetes as cause of ESRD and generally more comorbidity. Unadjusted proportional hazard results showed that pneumococcal vaccination was associated with a decreased hazard for mortality [hazard ratio (HR) 0.96, 95% confidence interval (CI) 0.92-1.0, P ¼ 0.044]. After adjustment for patient characteristics, comorbidity and receiving influenza vaccinations, pneumococcal vaccination was associated with a statistically significant decreased hazard for mortality (HR 0.94, 95% CI 0.90-0.98, P ¼ 0.005; Table 2 ). There was also a statistically significant association of vaccination with cardiac death (HR 0.91, 95% CI 0.85-0.97, P ¼ 0.005; Figure 1 ). The HR for infectious death was lower, but not significant (HR 0.87, 95% CI 0.74-1.02, P ¼ 0.09). For hospitalization outcomes (allcause, pneumonia and bacteremia/viremia/septicemia), HRs were all <1.0, but only the association of pneumococcal vaccination with bacteremia/viremia/septicemia was statistically significant (HR 0.95, 95% CI 0.91-1.00, P ¼ 0.048). Patients who received pneumococcal vaccinations were more likely to receive influenza vaccinations. Receiving a pneumococcal vaccination and an influenza vaccination in both influenza vaccination seasons during the entry period conferred slightly more (but not statistically significant) benefit than influenza vaccination alone (HR 0.76 for influenza vaccination in both seasons and 0.73 for influenza and pneumococcal vaccinations; Table 3 ). Results from the sensitivity analyses using 1 year of follow-up are similar to the primary results (data not shown). A very small number of patients received more than one pneumococcal vaccination (508 of the 25 091 who received at least one). Therefore, sensitivity results examining associations of more than one pneumococcal vaccination with outcomes generally were not informative (results not shown).
Discussion
The literature examining pneumococcal vaccination effectiveness in preventing a number of adverse outcomes is substantial with a wide range of findings, from extremely protective to harmful [5, [8] [9] [10] [11] [12] [13] [14] [15] [16] . A recent meta-analysis [8] essentially found little evidence of pneumococcal vaccination effectiveness for any outcomes examined. More studies have found an impact of vaccination for the outcome of invasive pneumococcal disease, and fewer studies have shown a relationship between vaccination and reduced risk of mortality. Some studies have shown decreased severity of illness among patients hospitalized with invasive pneumococcal disease who had previously received pneumococcal vaccinations. Impaired immunogenicity due to chronic disease, particularly ESRD, may limit the effectiveness of pneumococcal vaccination. Pourfarziani et al. [4] assessed this in hemodialysis and kidney transplant patients and found that initial response to vaccination as measured by anti-pneumococcal IgG levels was adequate; however, for hemodialysis patients in particular, serum antibody levels had declined dramatically when measured 1 year after vaccination. This finding suggests that the physiologic response to pneumococcal vaccination in ESRD may be attenuated, measuring serum antibody levels is important and more frequent vaccination than currently recommended may be necessary. Mahmoodi et al. [3] compared antibody response in chronic kidney disease patients with response in healthy controls. They found that while most chronic kidney disease patients showed a response, the response was less than in healthy controls, with lower antibody levels at 4 and more weeks episodes of pneumococcal infection. Although the number of patients who received more than one pneumococcal vaccination in our study was small, some models showed possible (although not statistically significant) evidence of a beneficial effect of more frequent vaccinations (data not shown), agreeing with the studies that show more rapid decline of serum antibody levels in patients with chronic disease.
Although pneumococcal vaccination may be administered year around, we found a seasonal effect, with more patients receiving pneumococcal vaccinations during the influenza immunization season and a higher likelihood of patients receiving both pneumococcal and influenza vaccinations. Goebel et al. [17] presented a similar relationship between the two vaccines. Because of this, we thought it is important to examine the impact of pneumococcal vaccination adjusting for influenza vaccination. We found a small additional protective effect for patients who received both vaccinations, compared with patients who received influenza vaccination only, particularly for those who received influenza vaccinations in two consecutive seasons. Information on incidence of pneumococcal pneumonia and influenza is generally lacking for hemodialysis patients. The most common organism coded in pneumonia hospitalization claims is 'unspecified', and therefore, incidence information related specifically to pneumococcal pneumonia is not available in Medicare data. The rate of hospital admissions for this non-specific category of pneumonia among hemodialysis patients is 73/1000 patientyears [1] . Regarding influenza, estimating influenza-related morbidity using claims is difficult, as influenza is not usually coded as a principal discharge diagnosis. However, influenza not uncommonly, leads to secondary complications, such as bacterial infections and exacerbations of chronic conditions, that lead to hospitalization (and therefore receive principal discharge diagnosis codes other than 'influenza'). The United States Renal Data System published information on hospitalizations for respiratory infection (a very broad category of codes that includes influenza) for pediatric patients in 2010 [18] , but this has not been done, to our knowledge, in the hemodialysis population generally.
Regarding study limitations, although we adjusted for a large number of patient characteristics and comorbid conditions, the possibility of residual confounding remains; patients who received pneumococcal or influenza vaccinations may be healthier than patients who were not vaccinated, in ways not captured in administrative data (and therefore not adjusted for). Another limitation involves the possibility that vaccination is a proxy for overall quality of care and that receiving a vaccination may be correlated with receiving other preventive health care measures. Also, patient misclassification is possible if a patient received the pneumococcal vaccination but no claim was submitted for payment. Since the current general recommendation is a vaccination once every 5 years, our use of a 2-year entry period may mean that we missed patients who received vaccinations before the 2-year entry window. This misclassification, however, would tend to attenuate findings toward a null effect. Use of an entry period >2 years would result in a presumably healthier cohort and reduce the sample size, and the 2-year period identified pneumococcal vaccinations more proximal to the start of follow-up. As our results suggest, and as is supported by other studies, the possible rapid decline in serum antibody levels may make this limitation less important.
In conclusion, we found a small but statistically significant association between pneumococcal vaccination and lower risk of all-cause and cardiovascular mortality, and, although generally not significant, some results suggest a possible association with lower risk of certain types of hospitalizations in long-term hemodialysis patients. These findings are despite the additional findings that patients who were most likely to receive pneumococcal vaccinations during the prior 2 years were older and more likely to be white, with generally more comorbidity, all factors associated with worse outcomes for patients on hemodialysis. Given these results, along with results from other studies suggesting relatively rapid decrease in serum antibody levels, and the very low risk associated with more frequent revaccination, it may be prudent to consider measuring antibody titers and revaccinating hemodialysis patients more frequently than every 5 years. Consideration should also be given to the design of a clinical trial to more thoroughly examine efficacy of pneumococcal vaccination in patients undergoing long-term hemodialysis. 
